SELLAS Life Sciences Group (SLS) Competitors $1.63 +0.08 (+5.16%) Closing price 04:00 PM EasternExtended Trading$1.64 +0.01 (+0.31%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SLS vs. DAWN, AUTL, KALV, AVBP, DNTH, VIR, ANAB, TSHA, ORGO, and TBPHShould you be buying SELLAS Life Sciences Group stock or one of its competitors? The main competitors of SELLAS Life Sciences Group include Day One Biopharmaceuticals (DAWN), Autolus Therapeutics (AUTL), KalVista Pharmaceuticals (KALV), ArriVent BioPharma (AVBP), Dianthus Therapeutics (DNTH), Vir Biotechnology (VIR), AnaptysBio (ANAB), Taysha Gene Therapies (TSHA), Organogenesis (ORGO), and Theravance Biopharma (TBPH). These companies are all part of the "pharmaceutical products" industry. SELLAS Life Sciences Group vs. Its Competitors Day One Biopharmaceuticals Autolus Therapeutics KalVista Pharmaceuticals ArriVent BioPharma Dianthus Therapeutics Vir Biotechnology AnaptysBio Taysha Gene Therapies Organogenesis Theravance Biopharma Day One Biopharmaceuticals (NASDAQ:DAWN) and SELLAS Life Sciences Group (NASDAQ:SLS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability. Do analysts prefer DAWN or SLS? Day One Biopharmaceuticals currently has a consensus price target of $25.33, suggesting a potential upside of 275.31%. SELLAS Life Sciences Group has a consensus price target of $7.00, suggesting a potential upside of 329.45%. Given SELLAS Life Sciences Group's higher possible upside, analysts plainly believe SELLAS Life Sciences Group is more favorable than Day One Biopharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Day One Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14SELLAS Life Sciences Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to DAWN or SLS? In the previous week, Day One Biopharmaceuticals had 3 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 10 mentions for Day One Biopharmaceuticals and 7 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 1.09 beat Day One Biopharmaceuticals' score of 0.86 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Day One Biopharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SELLAS Life Sciences Group 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals hold more shares of DAWN or SLS? 88.0% of Day One Biopharmaceuticals shares are held by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 6.2% of Day One Biopharmaceuticals shares are held by company insiders. Comparatively, 1.4% of SELLAS Life Sciences Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more risk & volatility, DAWN or SLS? Day One Biopharmaceuticals has a beta of -1.26, indicating that its stock price is 226% less volatile than the S&P 500. Comparatively, SELLAS Life Sciences Group has a beta of 2.26, indicating that its stock price is 126% more volatile than the S&P 500. Is DAWN or SLS more profitable? SELLAS Life Sciences Group has a net margin of 0.00% compared to Day One Biopharmaceuticals' net margin of -50.63%. Day One Biopharmaceuticals' return on equity of -19.01% beat SELLAS Life Sciences Group's return on equity.Company Net Margins Return on Equity Return on Assets Day One Biopharmaceuticals-50.63% -19.01% -16.99% SELLAS Life Sciences Group N/A -132.51%-92.79% Which has higher earnings and valuation, DAWN or SLS? SELLAS Life Sciences Group has lower revenue, but higher earnings than Day One Biopharmaceuticals. Day One Biopharmaceuticals is trading at a lower price-to-earnings ratio than SELLAS Life Sciences Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDay One Biopharmaceuticals$131.16M5.27-$95.50M-$0.95-7.11SELLAS Life Sciences Group$1M171.64-$30.88M-$0.32-5.09 SummaryDay One Biopharmaceuticals beats SELLAS Life Sciences Group on 9 of the 17 factors compared between the two stocks. Get SELLAS Life Sciences Group News Delivered to You Automatically Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLS vs. The Competition Export to ExcelMetricSELLAS Life Sciences GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$163.21M$3.11B$5.67B$9.83BDividend YieldN/A2.23%3.79%4.08%P/E Ratio-5.0920.3830.5825.12Price / Sales171.64365.09463.91116.12Price / CashN/A42.3037.4059.05Price / Book6.528.659.096.18Net Income-$30.88M-$54.65M$3.25B$264.89M7 Day Performance3.16%6.59%4.76%2.66%1 Month Performance-14.21%9.57%6.72%3.05%1 Year Performance28.35%14.06%30.51%25.05% SELLAS Life Sciences Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLSSELLAS Life Sciences Group2.8878 of 5 stars$1.63+5.2%$7.00+329.4%+29.2%$163.21M$1M-5.0910Positive NewsEarnings ReportDAWNDay One Biopharmaceuticals2.7843 of 5 stars$5.90-3.3%$25.33+329.4%-53.4%$624.84M$131.16M-6.2160AUTLAutolus Therapeutics3.0218 of 5 stars$2.47+6.0%$9.32+277.3%-48.5%$620.11M$10.12M-2.81330News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionKALVKalVista Pharmaceuticals4.0798 of 5 stars$12.51+0.8%$26.29+110.1%+3.7%$619.93MN/A-3.39100News CoverageAVBPArriVent BioPharma2.1824 of 5 stars$17.42-3.2%$39.29+125.5%-22.3%$615.48MN/A-4.6240News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionHigh Trading VolumeDNTHDianthus Therapeutics1.3235 of 5 stars$18.89+0.7%$53.00+180.6%-28.9%$603.32M$6.24M-5.8180News CoverageAnalyst RevisionVIRVir Biotechnology3.3692 of 5 stars$4.28-0.5%$30.25+606.8%-47.1%$597.34M$74.21M-1.07580ANABAnaptysBio3.1379 of 5 stars$20.00-4.9%$47.75+138.8%-42.4%$588.78M$91.28M-4.46100Analyst ForecastTSHATaysha Gene Therapies3.4999 of 5 stars$2.76+1.5%$8.17+195.9%+27.3%$583.88M$8.33M-8.12180News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionORGOOrganogenesis4.2312 of 5 stars$4.61+1.3%$7.50+62.7%+82.2%$577.84M$482.04M-32.93950TBPHTheravance Biopharma2.1025 of 5 stars$11.40-1.0%$21.33+87.1%+58.2%$576.02M$64.38M-9.66110News Coverage Related Companies and Tools Related Companies Day One Biopharmaceuticals Alternatives Autolus Therapeutics Alternatives KalVista Pharmaceuticals Alternatives ArriVent BioPharma Alternatives Dianthus Therapeutics Alternatives Vir Biotechnology Alternatives AnaptysBio Alternatives Taysha Gene Therapies Alternatives Organogenesis Alternatives Theravance Biopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLS) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SELLAS Life Sciences Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SELLAS Life Sciences Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access